Biotech "Tweets of the Week"
New year's Newsflow Before JP Morgan Healthcare Conference
(January 4-8, 2016)
Featuring:
$ACAD $CNAT $DVAX $EDIT $EPZM $MNKD $PTCT $QURE $RLYP $SNY $VRX
#JPM16 $XBI $IBB
Looking for past biotech highlights? Check out the Biotech Tweets of the Week archive.
CRISPR player Editas headlines IPO boomlet $EDIT
Editas files S1: https://t.co/rVmNnLbhUc
— Meg Tirrell (@megtirrell) January 4, 2016
IPO day in biopharma. Editas, Syndax, Corvus all file. Editas will trade under $EDIT
— Drew Armstrong (@ArmstrongDrew) January 4, 2016
just be aware Editas has no drugs in the clinic and S-1 has over 50 pages in the risk factor section but hey its CRISPR
— Dan Rosenblum (@sharkbiotech) January 4, 2016
@bradloncar $EDIT will be 1 of hottest IPOs in recent memory (unless broad mkt implodes). p.s. I never buy anything at an IPO.
— Roy Friedman (@DewDiligence) January 4, 2016
@tradeinthezone @amitkjolly @editasmed @srqstockpicker This will be the first one. Others are Caribou Biosciences and CRISPR Therapeutics.
— Brad Loncar (@bradloncar) January 4, 2016
US #biotech #IPO filings just before Xmas: TiGenix, Cancer Prevention Pharma, Proteostasis Therapeutics, Pulse Bioscences.
— Mandy Jackson (@ScripMandy) January 4, 2016
As excited as I am over Editas $EDIT IPO, this may be a candidate for waiting 6 months (depending on the build up exuberance).
— Jason (@JasonHolman5) January 5, 2016
Editas S-1: valued at $344 mm after summer B round? (Gates got 8.9% for $31 mm) maybe $1 billion at IPO? Not bad. h/t @cyrusharmon
— Antonio Regalado (@antonioregalado) January 5, 2016
@ScripMandy @LifeSciVC looks like we're about to get a lot of market health data #therealmhealth
— Todd Pelham (@BioBDTodd) January 5, 2016
recommend #CRISPR folk, fans and gawkers have a look @antonioregalado who is dissecting #EDITAS recent S-1, patent issues. Fun follow....
— Paul D. Rennert (@PDRennert) January 5, 2016
Editas' IPO Challenge: Edit Investor Expectations as well as Diseased Genes https://t.co/LjLeUycvNH $EDIT
— Adam Feuerstein (@adamfeuerstein) January 5, 2016
Curious to see whether $EDIT IPO will have coat tails effect for these other filings, or the reverse? (Looking at you, DFMO)
— Andrew G. (@BioDueDiligence) January 5, 2016
Of the eight new public S-1's in biotech this week, 4/8 are from Boston/Cambridge-based companies: Editas, Syndax, Visterra, and SpringBank.
— Bruce Booth (@LifeSciVC) January 6, 2016
Mannkind faces the end of the road for Afrezza $MNKD $SNY
$MNKD MANNKIND CORPORATION ANNOUNCES TERMINATION OF LICENSE AND COLLABORATION AGREEMENT WITH SANOFI $SNY
— Liquid Biopsy (@Liquid_Biopsy) January 5, 2016
I hate “I told you so” but I told you so. It’s a shame some people have lost so much money by refusing to believe $MNKD Afrezza reality.
— Adam Feuerstein (@adamfeuerstein) January 5, 2016
$MNKD seems to have ~2 qtrs of cash left as of Q3'15...and that includes the nov raise, so may be DOA in the next 3-4 months
— zach (@zbiotech) January 5, 2016
Never any need for afrezza- not unique or superior to current therapies. Cultish $mnkd longs deserve this for being close minded.
— DeadCatBill (@getbillasap) January 5, 2016
$MNKD EV still $600 million laughably high
— Dan Rosenblum (@sharkbiotech) January 5, 2016
$AMPH not down on $MNKD news b/c AMPH has multiyear "take-or-pay" contract 2supply bulk insulin2 MNKD,
— Roy Friedman (@DewDiligence) January 5, 2016
$MNKD is clearly better off just pulling afrezza from the mkt at this point
— zach (@zbiotech) January 5, 2016
Sanofi says Afrezza "never met even modest expectations" $SAN $MNKD
— Makiko Kitamura (@maki_kitamura) January 5, 2016
$MNKD Who saw that coming? I mean, besides everyone?
— Jon Gardner (@ByJonGardner) January 5, 2016
MannKind Perilously Close to Bankruptcy After Sanofi Exit https://t.co/gHZjS2MmKw via @TheStreet
Comment section is remarkably empty.
— PropThink (@PropThinker) January 5, 2016
$MNKD New CEO DeSisto could not attend, so no Q&A.
For the most important event of the last 12 months.
Maybe DeSisto resigned already
— Jake King (@FajaJake) January 5, 2016
so RBC thinks $MNKD is worth 3x what piper does?...target $0.15
— zach (@zbiotech) January 6, 2016
Biotechs raise money
It's raining offerings
— BioBuckTweet (@Bucktweet_Say) January 5, 2016
If you were worried abt biotech stocks under-performing broader market in ’16, the flood of offerings this week should tell you to panic.
— Adam Feuerstein (@adamfeuerstein) January 5, 2016
Most cumulative $ ever sought by small/midsized biotechs on 1day?If no, when was there more?
$ACAD $ADMS $CEMP $EPZM $OTIC $PRTA $SAGE $TXMD
— Roy Friedman (@DewDiligence) January 5, 2016
Late January last year there was a week where biotech companies raised $2.7 billion. So we still have a ways to go. https://t.co/t5grV8q1yl
— Brad Loncar (@bradloncar) January 5, 2016
What most people whining about biopharma equity offerings seem to forget is the amount of equity taken off the market in acquisitions.
— Schulz (@portefeuillefun) January 6, 2016
The companies that announced raises last night:
$OTIC -12.6%
$EPZM -19.6%
$PRTA -7.9%
$TXMD -9.0%
$SAGE -8.9%
$CEMP -10.9%
$ACAD -10.7%
— Brad Loncar (@bradloncar) January 6, 2016
$IBB too many Bios dialing 877-CASH-NOW at the same time
— Red Acre Investments (@redacre) January 6, 2016
@adamfeuerstein with $220 million already in the bank makes 0 sense
— Dan Rosenblum (@sharkbiotech) January 7, 2016
Here is a summary of recent follow-on discounts. Yuck! pic.twitter.com/wiwplwscWr
— Brad Loncar (@bradloncar) January 7, 2016
Is Citigroup & Leerink heroes for protecting their $EPZM clients OR do they lose future 2ndary biz b/c CEO cos look at pricing in disgust..?
— Zachary Prensky (@Zackfoot) January 7, 2016
I have been reminded that public financings announced this week have been a bit ugly. I was actually referring to private rounds.
— Michael Gilman (@michael_gilman) January 8, 2016
Dynavax and uniQure pick a bad day for good news $DVAX $QURE
$QURE and $DVAX -- big day tomorrow! Rise and shine guys!
— MAISA (@MaisaCorp) January 6, 2016
Why are you people getting so jacked about $QURE? You’ve forgotten the lessons from $BLUE that quickly?
— Adam Feuerstein (@adamfeuerstein) January 6, 2016
$QURE 2-patient 12-wk data won't be able to address the durability and variability issues that investors are most concerned about GT now...
— Andy Biotech (@AndyBiotech) January 7, 2016
$QURE Preliminary Topline Results From Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Trial https://t.co/9tiCuXDrlh
— Bio Stocks™ (@BioStocks) January 7, 2016
@JustEk33 Yes, this is the type of market where you are hesitant to even call something good news.
— Brad Loncar (@bradloncar) January 7, 2016
$QURE Phase I/II AMT-060-01 Study
Preliminary Top-line Results – Low-dose Cohort pic.twitter.com/K8eEQLwdnZ
— Joe (@GantosJ) January 7, 2016
$DVAX safety data looks good... 2x the AESI's bc trial randomized 2:1. And all were classified NOT due to vaccine
— Shane Blackmon (@shaneblackmon) January 7, 2016
$dvax statistically significant higher rate of seroprotection than Engerix-B in diabetic participants and in all participants as a group.
— BioResearch (@BioResearchFund) January 7, 2016
unfortunately $DVAX and $QURE released positive news on a very bad day
— BioResearch (@BioResearchFund) January 7, 2016
$DVAX HBV-23 data is actually BETTER than the previous P3 data, b/c HBV-10 had question marks about Wegener's, GBS, Basedow's. No Q's here.
— Billy Jacob (@Billy_Jacob) January 7, 2016
Here's an easy way to measure value of $QURE HemoB data: it CRUSHES SoC re efficacy, convenience, duration, & no doubt pharmacoeconomics
— Michael Goodman (@mikegoodma) January 7, 2016
UniQure's Gene Therapy Boosts Clotting in Two Hemophiliacs https://t.co/lb4lvHeucw $QURE $BLUE $ONCE #genetherapy
— Makiko Kitamura (@maki_kitamura) January 7, 2016
Chardan $QURE Success seen with preliminary top-line hemophilia B data QURE price target of $40
— dough (@tgtxdough) January 7, 2016
@jq1234t $DVAX and $QURE are definitely a small moral victory after all the crashes we’ve seen on data lately.
— Brad Loncar (@bradloncar) January 7, 2016
As seen on the stream
$biib welcomes the new year w a hearty round of price increases
— NathanAaron (@NathanAhron) January 4, 2016
Pleased to announce FDA Calendar https://t.co/DWxRfvxyfl + Pipeline database https://t.co/h90BnmiIkd have been updated. 2015 IPOs added soon
— BioPharmCatalyst (@crusadernz) January 4, 2016
The first 0.2% of the trading year seems pretty sucky
— Stan D'Andrea (@stanleydandrea) January 4, 2016
Let’s forget today happened. 2016 starts tomorrow!
— Brad Loncar (@bradloncar) January 4, 2016
$TGTX pps drop but not too surprised after a bad day for sector & the 1st trading day since the ATM increase.
— Jason (@JasonHolman5) January 5, 2016
FDA's Califf Up For 1st Confirmation Vote Next Week
https://t.co/EuVmYz9RXY
#FDA #RobertCaliff #Califf #pharma #biotech
— Donna Young (@ScripDonnaDC) January 5, 2016
FYI, from the $CNAT PR the results adjusted "for baseline, MELD, etiology; not adjusted for multiple testing" meaning not the straight data
— David Sobek (@dsobek) January 5, 2016
$CNAT Looks like emricasan works on everything but the stuff that matters. Cooked pic.twitter.com/OfcVDYmoVb
— PropThink (@PropThinker) January 5, 2016
Not all raises are bad, the ones from the companies I am long are strategic and value building :-P
— Alfredo Fontanini (@AF_biotech) January 5, 2016
@tgtxdough @bradloncar IMO aggregate placement results(discounts), green shoes, etc.will be key to near/mid term sector performance
— Walter T Dec CFA (@Wtdec) January 5, 2016
BREAKING: Valeant planning to appoint new leader as CEO Pearson remains hospitalized, new CEO would replace committee running co. now - DJ
— CNBC Now (@CNBCnow) January 5, 2016
$VRX Howard Schiller named Interim CEO
— Shane Blackmon (@shaneblackmon) January 6, 2016
@BioStocks $CELG multiple could expand in reaction to commercial execution and dataflow with IP overhang now removed. PT 149
— dough (@tgtxdough) January 6, 2016
@SheffStation Overall, lesson seems that you can invest in questionable execution w nice tech, but only if balance sheet provides protection
— Daniel Ward (@danwardbio) January 6, 2016
$SPY $IBB $XBI Not fun being a long biased swing trader these days... ugh, gonna have to start swinging the other way
— BioBreakout (@BioBreakout) January 6, 2016
large cap #biotech acting ok small and mid caps getting absolutely crushed
— Dan Rosenblum (@sharkbiotech) January 6, 2016
@sharkbiotech The companies raising now are getting slammed but maybe in two weeks we will be talking about how smart they were to raise
— David Sobek (@dsobek) January 6, 2016
Fewer than 10% of the ~455 biotech names I track are up right now. Ugly.
— David Miller (@AlpineBV_Miller) January 6, 2016
I am still waiting for my Santa Claus rally. $SPY $QQQ $IBB
— BioStockAddict (@BioStockAddict) January 6, 2016
At least many of my price targets are coming within range…
— Dan Smithey (@dan_smithey) January 6, 2016
$TLOG..$.50 now down 72%! Remember risk/reward? Getting crushed here! Difference b/w trader success & trader failure. The gains were there!
— Sheff (@SheffStation) January 6, 2016
Don't know how bio management handle it with clinical data. I've got 1 more day before checking results in CF cells and I'm so nervous!
— Michael Torres, PhD (@Mykalt45) January 7, 2016
$QURE would have pulled a $BLUE move, if these results were announced one year ago, different tape today
— BioBreakout (@BioBreakout) January 7, 2016
I like $RLYP but the Twitter cult around this stock and its prospects is unsettling. You people need to chill the fuck out.
— Adam Feuerstein (@adamfeuerstein) January 7, 2016
sidelines. Burnt enough in the first 3 days.
— avidresearch (@avidresearch) January 7, 2016
the knee-jerk in $RLYP this AM was nuts, stops and panic. remain cautious, broken stocks often retest bottoms within 2-3 months
— Olddogwithnewtrix (@olddoggnewtrix) January 7, 2016
Would be down 8% on this trade if we held. Amazing how quickly things change in Biotech.
— BioBounce.com (@BioBounce) January 7, 2016
Theranos Effect: Health-Tech Startups Now Face A "Burden Of Proof" - puhleese. When was there not a burden? https://t.co/Qrr5J9HLWx
— Bijan Salehizadeh (@bijans) January 7, 2016
$CELG down to pre settlement levels...lol
— happyycamperr (@happyycamperr) January 7, 2016
$RVNC is indeed a buyout target, but not by $AGN. @zbiotech
— Roy Friedman (@DewDiligence) January 7, 2016
@ChillzTrading $BIND terminating development in mCRPC given the "evolving treatment landscape"
— ohmsonite (@ohmsonite) January 7, 2016
$IWM $IBB being obliterated with $GLD $XAUUSD ripping, could not be more #RiskOff than that. Even $XLF looks like crap now, that's a problem
— Jean Fonteneau (@JFinDallas) January 7, 2016
@sharkbiotech I preferred tax loss selling season
— Ready. Fire. Aim. (@AliasAmongUs) January 7, 2016
I was 5% invested coming in to 2016. Apparently that was 5% too much. Still down 1% for the year. #FML
— DCam (@dcamtrades) January 7, 2016
Analysis of patients' co-payments and financial burden of specialty drugs https://t.co/aUpyqDa1ei
— Juan P. Serrate, DVM (@JPZaragoza1) January 7, 2016
+300 tomorrow just because
— Festo (@Festo50) January 7, 2016
$DVAX is my winner today +40.23% 2nd rank $QURE +15.90% 3rd rank $MSTX +4.6% All the rest play Titanic ;) blubb-blubb That's not normal!
— Kristina (@actaestfabulaXX) January 7, 2016
$kbio is the best performing bio over the last 3 weeks at unchanged
— Joshua B (@srqstockpicker) January 7, 2016
Down 8% or more today (cont'd): $cemp $pcrx $achn $rptp $ttph $ovas $espr $auph $rlyp ....
#yougetthepicture
$blue : -7%
— Joe (@Drchik23) January 8, 2016
$ACAD catching up on offering documents. Noticed ADP completion date now 2H16.Perhaps announced earlier but noting it for 1st time
— j l (@bio_clouseau) January 8, 2016
$ACRX
AcelRx Completes Protocol Review with FDA and Plans to Initiate Phase 3 Open-Label Study (IAP312)...
https://t.co/9feBkdDJ5n
— Tom Wrigley (@WrigleyTom) January 8, 2016
I know everyone says 2016 is going to be a difficult year, but with so many CNS catalysts I can hardly contain my excitement!
— Alfredo Fontanini (@AF_biotech) January 8, 2016
#FDA posts docs for Titan/Braeburn's opioid dependence implant, #Probuphine $TTNP https://t.co/BqPI96X89N
Background https://t.co/Fo47OxeqNV
— SAC Tracker (@FDAadcomm) January 8, 2016
$CELG gets 20% of vote in Evercore survey on which stock will move most w/JPM. $VRTX top acquisition idea. $BIIB top idea in 2016.
— PropThink (@PropThinker) January 8, 2016
$PTCT Completes Rolling NDA #FDA Submission for #Duchenne drug #Translarna (#ataluren)
https://t.co/wkyno2quy5
#DMD #pharma #biotech
— Donna Young (@ScripDonnaDC) January 8, 2016
@HumbleBioTrader Baker Bros r not slowing down let alone pulling back from bio sector. Bios will still outperform S&P in '16
— Raj R (@rajramaswamy) January 8, 2016
Added $tril
— Joshua B (@srqstockpicker) January 8, 2016
A milestone in the progress of foundation-funded (i.e. patient-funded) biopharmas https://t.co/toIQhsb6zd #DMD cc @eperlste @MyelinRepairFdn
— David Maizenberg (@biologypartners) January 8, 2016
Getting ready for #JPM16
@jfindallas I'm curious how $QURE reports. Would bad data would be bad for JPM16?
— Dan Smithey (@dan_smithey) January 4, 2016
@JFinDallas @dan_smithey I'm most curious to see if pops on good news get faded or if some gains hold. #JPM16 $xbi $ibb
— 23aloha (@23aloha) January 4, 2016
.@JohnCFierce 8.5 on a 10 scale? And you *promise*? You must be sitting on the biggest and secretest biopharma news embargo in years. #JPM16
— David Maizenberg (@biologypartners) January 5, 2016
Can we ban the words "innovative" and "unmet need" at #JPM16, so companies have to explain what they do w/o handwaving?
— Caroline Chen (@CarolineYLChen) January 6, 2016
Here’s final data on the #JPM16 breakout webcasts. 79 are doing it this year (vs about 50 last year). 196 still not. https://t.co/PIu44ddGPJ
— Brad Loncar (@bradloncar) January 7, 2016
Sentiments Likely To Be Overheard At #JPM16. https://t.co/SQ9mMAwA95
— Bruce Booth (@LifeSciVC) January 8, 2016
Reminder: Details for #JPM16 Tweetup. https://t.co/nLvqHvldKo
I hate that “tweetup” name. Just stop by for drink. Hang. Have fun. Say hi.
— Adam Feuerstein (@adamfeuerstein) January 7, 2016
Ok, y'all will know I won Powerball if I buy the 1st round at #JPM16 tweetup next week. Either way, looking forward to seeing everyone!!
— Laura Strong (@scientre) January 7, 2016